Amylyx Pharmaceuticals (AMLX): Assessing Valuation After a Sharp Rally and Recent Pullback [Yahoo! Finance]
Amylyx Pharmaceuticals, Inc. (AMLX)
Company Research
Source: Yahoo! Finance
Despite recent declines, its performance since the start of the year offers a different perspective for investors. See our latest analysis for Amylyx Pharmaceuticals. Recent moves for Amylyx Pharmaceuticals show momentum is cooling off a bit after the big run earlier this year. While the 1-day and 7-day share price returns are in the red, the stock is still up an impressive 215% year-to-date. Its 1-year total shareholder return of 75% demonstrates that longer-term investors have been well rewarded despite recent volatility. If you're interested in what other healthcare stocks are catching attention lately, you can check out the latest movers with our See the full list for free. With such a sharp rally behind it and shares still trading well below many analyst targets, the real question is whether Amylyx is now undervalued or if the market has already priced in the company's future prospects. Price-to-Book Ratio of 4.1: Is it justified? The latest trading price puts Amylyx
Show less
Read more
Impact Snapshot
Event Time:
AMLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMLX alerts
High impacting Amylyx Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AMLX
News
- Amylyx Pharmaceuticals (AMLX) Valuation Check As New GLP-1 Candidate AMX0318 Enters Development Stage [Yahoo! Finance]Yahoo! Finance
- Amylyx Pharmaceuticals (AMLX) Announces the Selection of AMX0318 as Development Candidate for PBH and Other Rare Diseases [Yahoo! Finance]Yahoo! Finance
- Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/SBusiness Wire
- Amylyx Pharmaceuticals (NASDAQ:AMLX) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=AMLX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall MarketBeat
- Is Early AMX0114 Safety Data Altering The Investment Case For Amylyx Pharmaceuticals (AMLX)? [Yahoo! Finance]Yahoo! Finance
AMLX
Earnings
- 11/6/25 - Beat
AMLX
Sec Filings
- 1/16/26 - Form 144
- 1/16/26 - Form 144
- 1/15/26 - Form 144
- AMLX's page on the SEC website